中国普通外科杂志 ›› 2021, Vol. 30 ›› Issue (3): 261-268.doi: 10.7659/j.issn.1005-6947.2021.03.003

• 专题研究 • 上一篇    下一篇

DEP结构域蛋白质1B在胰腺癌中的表达及其临床意义

李铭旭1,仲成成1,张功铭2,胡伟1, 3,王仲1, 3   

  1. (徐州医科大学附属连云港医院  1. 肝胆外科  2. 病理科,江苏 连云港 222001;3. 南京医科大学康达学院第一附属医院 肝胆外科,江苏 连云港 222001)
  • 收稿日期:2020-11-27 修回日期:2021-02-19 出版日期:2021-03-25 发布日期:2021-04-06
  • 通讯作者: 王仲, Email: 18961326366@189.cn;胡伟,Email: 2580734318@qq.com
  • 作者简介:李铭旭,徐州医科大学附属连云港医院硕士研究生,主要从事肝胆外科方面的研究。
  • 基金资助:
    国家自然科学基金资助项目(81900772);江苏省连云港市卫生计生科技资助项目(201802;201906);南京医科大学康达学院第一附属医院博士科研启动基金资助项目(BS202003)。

Expression of DEP domain protein 1B in pancreatic cancer and its clinical significance

LI Mingxu1, ZHONG Chengcheng1, ZHANG Gongming2, HU Wei1, 3, WANG Zhong1, 3   

  1. (1. Department of Hepatobiliary Surgery 2. Department of Pathology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu 222001, China; 3. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222001, China)
  • Received:2020-11-27 Revised:2021-02-19 Online:2021-03-25 Published:2021-04-06

摘要: 背景与目的:已有研究显示,DEP结构域蛋白质1B(DEPDC1B)在多种肿瘤中异常表达并在肿瘤进展中发挥重要作用,DEPDC1B在胰腺癌中的表达水平及临床意义尚不清楚。本研究通过检测胰腺癌组织中DEPDC1B的表达,分析其与胰腺癌患者临床病理特征及预后的关系,从而探讨其在胰腺癌中的临床意义。
方法:下载癌症基因组图谱(TCGA)和高通量基因表达数据库(GEO)的胰腺癌患者临床数据,分析DEPDC1B在胰腺癌组织中的表达情况,采用Kaplan-Meier生存曲线及Cox风险模型分析DEPDC1B表达与胰腺癌患者预后的关系。采用免疫组织化学法检测97例胰腺癌组织和癌旁组织中DEPDC1B的表达,根据患者临床资料进一步分析DEPDC1B与胰腺癌临床病理特征以及胰腺癌患者预后的关系。
结果:在TCGA与GEO的GSE16515、GSE15471和GSE28735数据集中,DEPDC1B在胰腺癌组织中的表达明显高于匹配的正常组织(均P<0.05);在TCGA数据库与GSE28735数据集中,DEPDC1B高表达胰腺癌患者生存时间明显缩短(均P<0.05);TCGA中DEPDC1B表达是胰腺癌患者预后的独立危险因素(HR=1.32,95% CI=1.118~1.559,P=0.001)。97例临床胰腺癌患者中,胰腺癌组织中DEPDC1B的阳性表达率明显高于癌旁组织胰腺组织(69.07% vs. 11.34%,P<0.001);DEPDC1B的表达与分化程度、临床分期及淋巴结转移有关(均P<0.05);DEPDC1B高表达患者总生存期明显短于低表达患者(P<0.05);DEPDC1B表达是预后的独立危险因素(HR=1.126,95% CI=1.012~1.253,P=0.029)。
结论: DEPDC1B高表达可能参与胰腺癌的发生、发展及转移过程,并可作为判断胰腺癌预后的重要指标。

关键词: 胰腺肿瘤;DEP结构域蛋白质1B;预后;生物标记, 肿瘤

Abstract: Background and Aims: Previous studies have shown that DEP domain protein 1B (DEPDC1B) is abnormally expressed in a variety of tumors and plays an important role in tumor progression. However, the expression level and clinical significance of DEPDC1B in pancreatic cancer are still unclear. Therefore, this study was aimed to investigate the clinical significance of DEPDC1B in pancreatic cancer by determining the DEPDC1B expression in pancreatic cancer tissue and its association with the clinicopathologic parameters and prognosis of pancreatic cancer patients.  
Methods: The clinical data of pancreatic cancer patients were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and then, the DEPDC1B expressions in pancreatic cancer tissue were analyzed, and the relation of DEPDC1B expression with the prognosis of pancreatic cancer patients was determined by Kaplan-Meier survival curve and Cox risk model. The DEPDC1B expression in 97 paired specimens of pancreatic cancer and adjacent normal tissues was detected by immunohistochemical staining, and the associations of DEPDC1B expression with clinicopathologic variables and prognosis were evaluated. 
Results: The DEPDC1B expression of in pancreatic cancer tissue was significantly higher than that in matched normal tissues in TCGA database and the GSE16515, GSE15471 and GSE28735 datasets of GEO database (all P<0.05); the survival time of pancreatic cancer patients with high DEPDC1B expression was significantly shortened in TCGA database and GSE28735 dataset; DEPDC1B expression was an independent risk factor for the prognosis of pancreatic cancer patients in TCGA database (HR=1.32, 95% CI=1.118–1.559, P=0.001). In the 97 clinical pancreatic cancer patients, the positive DEPDC1B expression rate was significantly higher in pancreatic cancer tissue than that normal tissue (69.07% vs. 11.34%, P<0.001); the DEPDC1B expression was significantly associated with the degree of differentiation, clinical stage and lymph node metastasis (all P<0.05); the overall survival of patients with high DEPDC1B expression was shorter than that of patients with low DEPDC1B expression; the DEPDC1B expression was an independent risk factor  for prognosis (HR=1.126, 95% CI=1.012–1.253, P=0.029). 
Conclusion: High DEPDC1B expression may be involved in the occurrence, development and metastasis of pancreatic cancer, and it can be used as a prognostic biomarker for pancreatic cancer patients.

Key words: Pancreatic Neoplasms, DEP Domain Protein 1B, Prognosis, Biomarkers, Tumor

中图分类号: 

  • R735.9 
[1] 韩仕锋, 金春风, 朱磊. 预后指数在可切除胰腺导管腺癌患者术后评估中临床价值[J]. 中国普通外科杂志, 2021, 30(3): 247-253.
[2] 秦雯, 陈泰文, 郑海平, 杨建宇, 朱小东. 血清ANGPTL2与胰腺癌临床病理特征的关系及其在胰腺癌诊断中的价值[J]. 中国普通外科杂志, 2021, 30(3): 254-260.
[3] 刘向梅, 许达峰, 王春玲, 符于正, 王丹, 武金才. NIMA相关激酶2在胰腺癌中的表达及其临床意义[J]. 中国普通外科杂志, 2021, 30(3): 269-275.
[4] 张波, 徐涛, 徐浩, 夏雨, 周文策, . 基于生物信息学胰腺腺癌关键基因的筛选及支持向量机诊断模型的构建[J]. 中国普通外科杂志, 2021, 30(3): 276-285..
[5] 李威威, 刘金龙. 循环肿瘤DNA在胰腺癌中的临床应用进展[J]. 中国普通外科杂志, 2021, 30(3): 337-342.
[6] 谢学文, 费书珂. 中性粒细胞胞外诱捕网与胰腺疾病的研究进展[J]. 中国普通外科杂志, 2021, 30(3): 343-348.
[7] 周艳, 陈超, 杨竹林, 熊力. 长链非编码RNA在肝细胞性肝癌中的作用[J]. 中国普通外科杂志, 2021, 30(3): 349-356.
[8] 王蒲雄志, 于新哲, 史向军, 袁周 . 胰腺导管腺癌的免疫治疗研究进展 [J]. 中国普通外科杂志, 2021, 30(3): 330-336.
[9] 牛恒, 杨昆宪. 免疫微生态肠内营养联合加速康复策略对结直肠癌患者术后免疫状态的影响[J]. 中国普通外科杂志, 2021, 30(3): 369-374.
[10] 卓恩挺, 王连臣, 符国宏, 潘建民. 腹腔镜下腹会阴直肠癌手术中腹膜外造口与腹膜内造口的疗效比较[J]. 中国普通外科杂志, 2021, 30(2): 241-246.
[11] 韩伟光, 莘玮, 苏水霞, 王青. 基于生物信息学的胆囊癌差异表达谱中关键蛋白调控基因分析[J]. 中国普通外科杂志, 2021, 30(2): 165-172.
[12] 周京涛, 刘佳, 努尔买买提·阿米都拉, 闫军, 寇旭东, 张鸽文. 上调lncRNA SNHG12与miR-199a-5p/FZD6轴对肝细胞癌细胞增殖、侵袭和上皮-间质转化的影响[J]. 中国普通外科杂志, 2021, 30(2): 173-186.
[13] 刘继升, 刘河, 刘浩, YU Xing, 李浩. TIP30在肝内胆管癌中的表达及意义[J]. 中国普通外科杂志, 2021, 30(2): 187-194.
[14] 陈伟钊, 吴嘉艺, 黄晓晓, 吕嘉晖, 黄理铭, 严茂林 . “q”形胆管切开取栓术在肝细胞癌伴B4型胆管癌栓治疗中的应用价值[J]. 中国普通外科杂志, 2021, 30(2): 151-157.
[15] 张帆, 李泽东, 彭禹, 陈胜, 周钧. 基于血清miRNA表达数据的胰腺癌诊断决策树构建[J]. 中国普通外科杂志, 2021, 30(2): 211-218.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 龚丽, 欧阳文, 裴琛琳, 陈志康, 朱红, 董超, . 妊娠合并BRAF突变晚期结肠癌国际会诊病例诊治体会并文献复习[J]. 中国普通外科杂志, 2020, 29(4): 510 -514 .
[2] 赵文娟, 朱燕梅, 李晓玲, 秦洁 . 基于微信平台的围手术期干预在乳腺癌全程个案管理中的应用[J]. 中国普通外科杂志, 2020, 29(5): 630 -634 .
[3] 肖卫星,周君,顾梦佳,肖广远. 精准肝切除在肝内胆管结石手术治疗中的应用[J]. 中国普通外科杂志, 2016, 25(2): 191 -196 .
[4] 杨艳婷, 鲁明典, 夏俊, 郑慧, 童清平, 毛萍 . 腔内超声与高分辨薄层直肠MRI新序列在术前评估与直肠癌术后病理结果的对比分析[J]. 中国普通外科杂志, 2020, 29(4): 498 -503 .
[5] 白宁1, 2|王栋2|欧阳锡武2|周乐杜2|王志明2. 苦参碱对大鼠肝缺血再灌注损伤的抑制作用及机制[J]. , 2018, 27(1): 81 -86 .
[6] 肖润沙, 唐文彬, 陈子华, 成小苗. 胃肠道肿瘤合并肾损害30例报告并文献复习[J]. 中国普通外科杂志, 2020, 29(4): 504 -509 .
[7] 黄隽, 胡元萍, 陈创, 齐晓伟. 新型冠状病毒肺炎疫情特殊时期对乳腺癌治疗临床问题的若干思考[J]. 中国普通外科杂志, 2020, 29(2): 153 -160 .
[8] 廖信芳1,李正荣2,杨清水1,张乡城2, 李柱1,揭志刚2. microRNA-139-5p及其靶基因Notch1在结直肠癌中的作用[J]. 中国普通外科杂志, 0, (): 1373 -1378 .
[9] 项灿宏|童翾 . 肝门部胆管癌外科治疗的进展与争议[J]. , 2018, 27(2): 137 -142 .
[10] 黄耿文|申鼎成|何文|杨柳|周书毅|阳建怡|纪连栋|魏伟. 快速康复模式下的腹腔镜腹股沟疝修补术[J]. , 2016, 25(10): 1470 -1474 .